Key Takeaways Progressive faces tariff-linked claims cost pressure but gains from digital-first strategies.PGR's Snapshot, Smart Haul and analytics tools enhance pricing and reduce loss exposure.Estimates for PGR's 2025 EPS and revenues have moved higher, signaling expected growth.The Progressive Corporation (PGR) , one of the largest U.S. auto insurers, is relatively well-positioned to manage tariff-related challenges under the Trump administration, leveraging its operational strengths while facing certain ...

Analysts are mixed on INTU, with 27 firms firms maintaining a "buy" or better rating and the other 11 leaning "hold" or worse. J.P. Morgan Securities, Morgan Stanley, and Barclays Securities also cut their price targets, while RBC Capital Securities is standing firm with an outperform rating. Bearish sentiment is building in the options pits today, though, with 13,000 puts traded versus 10,000 calls, volume that's eight times the amount seen at this point. The most active contract is the September 650-strik ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Key Takeaways RLI's product diversification, rate increases, and expanded distribution support strong top-line growth.RLI has delivered 29 straight years of underwriting profitability, underscoring operational strength.The insurer has raised regular dividends for 50 years, plus paid special dividends since 2011.Shares of RLI Corp. (RLI) have lost 9.6% in the past year against its industry, the Finance sector and the Zacks S&P 500 composite’s return of 7.5%, 16% and 14.3%, respectively.Closing at $68.40 on T ...

Join us today to have access to our portfolio, watchlist and live chat. Members get the first look at all publications and even exclusive articles not posted elsewhere. Check out Cash Builder Opportunities, where we provide ideas about high-quality and reliable dividend growth ideas. These investments are designed to build growing income for investors. A special focus on investments that are leaders within their industry to provide stability and long-term wealth creation. Along with this, the service provid ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

As a tech-focused industry Research Analyst, I aim to provide differentiated insights, whether it is for investing, trading, or informational reasons. For this purpose, I am not a classical equity researcher from the financial sector, but, I come from the IT world as the Director of Keylogin InfoTech and my insights are based on my own experience investing for 25 years.Also, my research is often backed by analytics and I make frequent use of charts to support my position.Based on losses during the GFC, I am ...

On Friday, Takeda Pharmaceutical Co Ltd's TAK stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday. On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.'s IONS Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. Investors should note that Takeda also has a hereditary angioedema prevention dru ...

Key Takeaways Q2 EPS of $1.56 beat estimates, but dipped 1.9% YoY due to tariffs.Sales rose 5% YoY to $5.53B; comps improved 2%, led by cosmetics segment and Southeast & Midwest region.Stronger sales trends lift ROST's Q2, but tariff costs curbed EPS growth; management guides caution into Q3.Ross Stores, Inc. (ROST) reported second-quarter fiscal 2025 results with earnings beating the Zacks Consensus Estimate, though sales fell slightly short. Net sales rose compared with the prior year, but earnings per sh ...

Friday, August 22, 2025A half hour after the opening bell for the final trading day of the week, Fed Chair Jerome Powell will take the stage at the Jackson Hole Economic Symposium this morning, in one of his most anticipated Jackson Hole speeches in years. Investors will be listening closely to hear if the deliberate and methodical Powell will be leaning toward a 25-basis-point (bps) interest rate cut.The Fed has kept rates steady year-to-date at 4.25-4.50%. In historical terms, we’re neither high nor low — ...